Dogwood Therapeutics, Inc. 8-K

What Happened
Dogwood Therapeutics, Inc. (DWTX) filed a Form 8-K on May 14, 2026 (Item 2.02) to announce its results of operations for the quarter ended March 31, 2026. The company furnished a press release dated May 14, 2026 reporting those quarterly results (included as Exhibit 99.1 and incorporated by reference into the filing).

Key Details

• Filing date: May 14, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: Quarter ended March 31, 2026 (first quarter 2026).
• Disclosure vehicle: Press release dated May 14, 2026 (Exhibit 99.1 to the Form 8-K).
• Filing signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer, on behalf of the company.

Why It Matters
This 8-K provides Dogwood’s official quarterly update on operating results and is the primary source for investors seeking recent information on the company’s quarterly performance, including earnings, revenue and other operating metrics disclosed in the press release. Retail investors should review the furnished press release and any accompanying investor materials or subsequent SEC filings for the specific financial figures and context before making decisions.